文献速递类风湿关节炎

阿巴西普或TNF阻断剂对类风湿关节炎循环Tfh细胞的差异化调节及治疗反应预测

Circulating Tfh cells are differentially modified by abatacept or TNF blockers and predict treatment response in rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

研究纳入长期血清阳性类风湿关节炎患者,比较阿巴西普(ABT)或TNF阻断剂(TNFb)对循环滤泡辅助性T细胞频率的影响,并在启动治疗患者中评估基线频率对12个月缓解的预测价值。ABT可降低循环Tfh频率至健康对照水平而TNFb不能,较高基线频率预示ABT良好应答但TNFb应答不佳。

要点

  • 阿巴西普可降低类风湿关节炎患者循环Tfh细胞频率,TNF阻断剂无此作用。
  • 阿巴西普组基线循环Tfh频率>0.38%者12个月缓解几率更高(OR 25.3)。
  • TNF阻断剂组基线循环Tfh频率>0.44%者12个月未缓解几率更高(OR 8.5)。

核心结论

  • 阿巴西普而非TNF阻断剂能够降低类风湿关节炎患者的循环Tfh细胞频率。
  • 较高的基线循环Tfh频率预示对阿巴西普的良好应答但对TNF阻断剂的不良应答。

研究设计与样本

  • 横断面研究比较长期接受csDMARDs(n=45)、TNFb(n=59)或ABT(n=34)的血清阳性长病程RA患者与健康对照(n=137)的循环Tfh频率。
  • 另对csDMARDs应答不完全并启动TNFb(n=19)或ABT(n=22)的患者(n=41)在0和12个月检测循环Tfh频率。
  • 循环Tfh频率通过流式细胞术检测。

主要发现

  • 与健康对照相比,长期接受csDMARDs或TNFb的血清阳性长病程RA患者循环Tfh频率升高,而ABT组未升高。
  • 从csDMARDs转换后,TNFb组循环Tfh频率无变化,ABT组降至健康对照水平。
  • ABT组中达到12个月缓解者基线循环Tfh频率高于仍活动者:0个月缓解截断值>0.38%(敏感度92%,特异度90%,OR 25.3)。
  • TNFb组中达到12个月缓解者基线循环Tfh频率低于仍活动者:0个月未缓解截断值>0.44%(敏感度67%,特异度90%,OR 8.5)。

关键数值与推荐

  • ABT组12个月缓解的0个月循环Tfh频率截断值>0.38%,敏感度92%,特异度90%,OR 25.3。
  • TNFb组12个月未缓解的0个月循环Tfh频率截断值>0.44%,敏感度67%,特异度90%,OR 8.5。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: CD4+CXCR5+PD-1hi follicular helper T (Tfh) cells dwell in the germinal centres (GCs) of lymphoid organs and participate in RA pathogenesis. The frequency of their circulating counterparts (cTfh frequency) is expanded in RA and correlates with the pool of GC Tfh cells. Our objective was to study the effect of abatacept (ABT) or TNF blockers (TNFbs) on the cTfh frequency in RA. METHODS: Peripheral blood was drawn from seropositive, long-standing RA patients chronically receiving conventional synthetic DMARDs (csDMARDs; n = 45), TNFb (n = 59) or ABT (n = 34) and healthy controls (HCs; n = 137). Also, patients with an incomplete response to csDMARDs (n = 41) who initiated TNFb (n = 19) or ABT (n = 22) were studied at 0 and 12 months. The cTfh frequency was examined by cytometry. RESULTS: As compared with HCs, an increased cTfh frequency was seen in seropositive, long-standing RA patients chronically receiving csDMARDs or TNFb but not ABT. After changing from csDMARDs, the cTfh frequency did not vary in patients who were given TNFb but decreased to HC levels in those given ABT. In the ABT group, the baseline cTfh frequency was higher for patients who attained 12-month remission (12mr) vs those who remained active (12ma): 0 month cut-off for remission >0.38% [sensitivity 92%, specificity 90%, odds ratio (OR) 25.3]. Conversely, in the TNFb group, the baseline cTfh frequency was lower for 12mr vs 12ma: 0 month cut-off for non-remission >0.44% (sensitivity 67%, specificity 90%, OR 8.5). CONCLUSION: ABT but not TNFb was able to curtail the cTfh frequency in RA. A higher baseline cTfh frequency predicts a good response to ABT but a poor response to TNFb.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Monjo-Henry I, Uyaguari M, Nuño L, et al. Circulating Tfh cells are differentially modified by abatacept or TNF blockers and predict treatment response in rheumatoid arthritis. Rheumatology (Oxford). 2025. PMID: 38321365. doi:10.1093/rheumatology/keae090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。